FDA Approval Propels ZVRA To 52-week High, ADMA, CPRX, TVTX Also Reach New Peaks
==========

Zevra Therapeutics Inc. (ZVRA) received FDA approval for MIPLYFFA on September 20, 2024, for treating Niemann-Pick disease type C; this approval led ZVRA shares to a 52-week high of $8.81; other stocks like ADMA Biologics Inc. (ADMA), Catalyst Pharmaceuticals Inc. (CPRX), and Travere Therapeutics Inc. (TVTX) also reached new peaks; ZVRA's last closing price was $8.06; ADMA's last closing price was $19.98, and CPRX's was $20.79.

#Fda #ZevraTherapeutics #Biotech #StockMarket #NiemannpickDisease #Miplyffa #Adma #Cprx #Tvtx #Investments

https://www.rttnews.com/3476575/fda-approval-propels-zvra-to-52-week-high-adma-cprx-tvtx-also-reach-new-peaks.aspx